CrushSCI.com
126.0Average days
123Median days
31Fastest days
255Longest days
3582025 publications

Paper Review Records

All Paper Review Records

30 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

62 days

An In Silico–In Vitro Framework for Model‐Informed Precision Dosing in Oncology: Proof‐of‐Principle for Doxorubicin in Patient‐Derived Sarcoma Spheroids

Authors
Hannah K. Dorn; Micaela Freitas; Severin Manser; Marko Weidmann; Ina Oehme; Heike Peterziel; Olaf Witt; Jens M. Kelm; Lars KuepferShow moreShow less
Affiliations
1. Institute for Systems Medicine With Focus on Organ Interaction University Hospital RWTH Aachen University Aachen Germany; 2. PreComb Therapeutics AG Hombrechtikon Switzerland; 3. Hopp Children's Cancer Center Heidelberg (KiTZ) Heidelberg Germany; 4. Clinical Cooperation Unit Pediatric Oncology (B310) German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) Heidelberg Germany; 5. National Center for Tumor Diseases Heidelberg Heidelberg Germany; 6. Department of Pediatric Oncology, Hematology, Immunology and Pulmonology Heidelberg University Hospital Heidelberg GermanyShow moreShow less
Source PDF DOI Publisher page
88 days

Nine‐Year Trends in Treatment Patterns, Comorbidities, and Healthcare Utilization in Type 2 Diabetes in France: Insights From Integrated Health Data

Authors
Romane Le Goff; Amandine Gouverneur; Cédric Collin; Pascaline Rabiega; Mathieu MolimardShow moreShow less
Affiliations
1. Real World Solutions IQVIA Paris France; 2. Department of Medical Pharmacology Bordeaux University Bordeaux FranceShow moreShow less
Source PDF DOI Publisher page
141 days

The Relationship Between Pre‐Operative Ipilimumab and Nivolumab Pharmacokinetics and Treatment Outcome in Locoregionally Advanced Urothelial Cancer

Authors
Sybrand W. J. Zielhuis; Karen A. M. de Jong; Hinke Huisman‐Siebinga; Lisa T. van der Heijden; Bart A. W. Jacobs; Jos H. Beijnen; Hilde Rosing; Chantal F. Stockem; Jeroen van Dorp; Michiel S. van der Heijden; Alwin D. R. HuitemaShow moreShow less
Affiliations
1. Department of Pharmacy & Pharmacology The Netherlands Cancer Institute Amsterdam the Netherlands; 2. Department of Medical Oncology The Netherlands Cancer Institute Amsterdam the Netherlands; 3. Department of Molecular Carcinogenesis The Netherlands Cancer Institute Amsterdam the Netherlands; 4. Department of Clinical Pharmacy University Medical Center Utrecht, Utrecht University Utrecht the Netherlands; 5. Princess Máxima Center for Pediatric Oncology Utrecht the NetherlandsShow moreShow less
Source PDF DOI Publisher page
104 days

Application of Mechanistic Modeling to Support Dose‐Relevant Decision Making for CAR ‐T Cell Therapy in Oncology: A Systematic Scoping Review

Authors
Dolapo Odujinrin; Graham McClellandShow moreShow less
Affiliations
1. Centre for Pharmaceutical Medicine Research, School of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London London UKShow moreShow less
Source PDF DOI Publisher page
76 days

Healthy Participant Versus Patient Selection for Clinical Pharmacology Studies in Small‐Molecule Oncology Drug Development

Authors
Paridhi Gupta; Zheyi Hu; Li Zhu; Lora HamuroShow moreShow less
Affiliations
1. Clinical Pharmacology Bristol Myers Squibb Princeton New Jersey USAShow moreShow less
Source PDF DOI Publisher page
132 days

Landscape Analysis of Digital Health Technology Use for Remote Data Acquisition in CDER ‐Regulated Submissions, 2023–2025

Authors
Ayoub Suliman; Norah Xiao; Leonard Sacks; Elizabeth Kunkoski; Ryan Robinson; Dianne Paraoan; Hussein Ezzeldin; Anindita Saha; Qi Liu; Hao Zhu; Yutao Gong; Hanrui Zhang; Ruihao Huang; Jeffrey Siegel; Jonas Santiago; Elizabeth HartShow moreShow less
Affiliations
1. Office of Medical Policy, Center for Drug Evaluation and Research U.S. Food and Drug Administration Silver Spring Maryland USA; 2. Office of Translational Sciences, Center for Drug Evaluation and Research U.S. Food and Drug Administration Silver Spring Maryland USA; 3. Office of Drug Evaluation Sciences, Office of New Drugs, Center for Drug Evaluation and Research U.S. Food and Drug Administration Silver Spring Maryland USAShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does CTS-Clinical and Translational Science take to review a manuscript?

As of 2026-11-17, CrushSCI has 30 complete review records for CTS-Clinical and Translational Science. The fastest paper went from submission to acceptance in 31 days (Posaconazole Target Attainment in Critically Ill Children: A 15‐Year Single‐Center Retrospective Analysis, received 2026-07-24, accepted 2026-08-24); the slowest took 255 days. The average is 126.0 days and the median is 123 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.